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Fragile X syndrome (FXS) is the most common inherited cause of intellectual disability due to an expansion in the full mutation
range (>200 CGG repeats) of the promoter region of the FMR1 gene leading to gene silencing. Lack of FMRP, a critical protein
for dendritic spine formation and maturation, will cause FXS. Early environmental enrichment combined with pharmacological
intervention has been proven to rescue dendritic spine abnormalities in the animal model of FXS. Here we report on 2 young
children with FXS who were treated early with a combination of targeted treatment and intensive educational interventions leading
to improvement in their cognition and behavior and a normal IQ.
1. Introduction
Fragile X syndrome (FXS) is caused by a CGG trinucleotide
repeat expansion located in the 5′ untranslated region (UTR)
of fragile X mental retardation 1 (FMR1) gene. When the
CGG expansion is >200 repeats, there is silencing of tran-
scription through methylation and a subsequent deficit or
absence of fragile X mental retardation protein (FMRP), the
protein product of FMR1 gene. FMRP is an RNA-binding
protein that transports and stabilizes messenger ribonucleic
acids (mRNAs) to the synapse, where it regulates protein
synthesis usually through suppression of translation [1, 2].
The allele frequency of the full mutation is about 1 in 2500 in
the general population [3].
The lack of FMRP leads to a combination of cognitive
impairments, behavioral problems, and physical features,
including prominent ears and hyperextensible finger joints
that are the phenotype of FXS [4]. There are the behavioral
and developmental problems in childhood and a variety of
medications have been helpful for treating anxiety, aggres-
sion, attention deficit hyperactivity disorders (ADHDs), and
mood instability [5].
The absence of FMRP causes impairment of synaptic
plasticity [6] that includes upregulation of various pro-
teins including matrix metalloproteinase 9 (MMP9) [7],
upregulation of the metabotropic glutamate receptor 5
(mGluR5) pathway [8], and downregulation of the gamma-
aminobutyric acid (GABA) receptors [9, 10]. The devel-
opment of targeted treatments for FXS has led to trials
of minocycline [11, 12], Arbaclofen [13] and mGluR5
antagonists [14, 15] in patients with FXS.
Normal intelligence quotient (IQ) is uncommon inmales
with FXS (13%) and these individuals typically have an
unmethylation fully expanded FMR1 gene mutation [16].
Approximately from 30 to 50% of females with FXS can have
a normal IQ [17, 18], and these individual have a favorable
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activation ratio and higher FMRP level [19]. Here we present
2 cases of children with the FXS who have had a remarkable
response to combined interventions and a normal IQ.
2. Case Report
Case 1 is a 3-year-old boy carrying a full mutation allele
with 245, 310, 523, 723, 1030, and 1360 CGG repeats,
and 90% of his FMR1 alleles are methylated. Mother had
normal pregnancy and delivered full term by C-section
due to preeclampsia, and he was 3700 grams at birth and
suﬀered from torticollis and frequent emesis in the first
year of life. His developmental milestones were delayed
with sitting at 7-8 months, crawling at 14 months, walking
independently at 18 months, and saying single words at
2.5 years and short sentences at 3 years. He has behavior
problems including severe tactile defensiveness, poor eye
contact, hyperactivity, and intermittent aggression. At age 2
years and 6 months he started sertraline at 2.5mg/day with
a subsequent dramatic improvement in expressive language
described as an “explosion of verbalizations” and the onset
of phrases in speech. Minocycline (12.5mg/day) was started
two months before he turned three years, and improvement
was seen in his anxiety and aggression. Minocycline was
discontinued after 4-month treatment, resulting in the
return of his behavior problems including frequent biting,
chewing on his shirt, and an increase in his anxiety, so it
was restarted. In conjunction withmedication, he received 30
hours of physical therapy during his first year of life. After age
2 he received 1 hour of occupational therapy monthly. Now,
he attends a day care program for children with special needs
for 3 hours/day, 3 days per week. Additionally, his mother,
who is a teacher at a vocational school, applies elements
of Montessori homeschooling into his daily routine. The
educational intervention emphasizes age-appropriate games
and exercises in order to promote cognition and memory,
concentration, speech, and fine and gross motor skills (e.g.,
singing, looking at books, applying Montessori materials,
etc.).
Examination at age 3 years and 2 months demonstrated
normal growth percentiles, hyperextensible finger joints, and
severe flat feet. On the Stanford-Binet his full-scale IQ was
94 with a nonverbal of 97 and a verbal of 92, fluid reasoning
was 97, overall knowledge 111, quantitative reasoning 89,
visual spatial abilities 94, and working memory 86. On the
Autism Diagnostic Observation Scale (ADOS), he scored in
the normal range. On the Vineland Adaptive Behavior (VAB)
Scales, his communication score was 85, daily living skills 91,
socialization 79, and overall adaptive behavior composite 86.
His motor composite on the McCarthy Scales of Children’s
Ability was in the average range with a scale index of 54.
Case 2 is the sister of case 1, 7 years 11 months with a full
mutation allele (260–370 CGG repeats), and an activation
ratio was 0.2 (only 20% of her calls have the normal X as
the active X) in peripheral blood lymphocytes. Her mother’s
pregnancy was complicated by preeclampsia in the last week,
and she was delivered by C-section; birth weight was 2980
grams. She was hypotonic, and her developmental milestones
were mildly delayed, sitting at 10 months, crawling at
12 months, walking at 16 months, saying words at 20
months, and putting together phrases at 3 years of age.
However, her behavioral and emotional problems have been
significantly problematic. When she was 20 months, she
intermittently refused to walk and she had episodes of
selective mutism. She had anxiety on a daily basis, poor
eye contact, moodiness, tactile defensiveness, perseveration,
and shyness with impaired social interactions. She is in the
second grade attending regular school, but she demonstrates
learning disabilities in math, reading, and writing.
Psychopharmacological intervention included meman-
tine 5mg/day started at age 7 with remarkable improvement
in reading, writing, and behavior. Three months later,
20mg/day of sertraline was added which improved her
anxiety. Seven months later, minocycline (12.5mg/day) was
added, and it was helpful for math academically. Minocycline
was discontinued during the summer holiday, and her
math abilities rapidly deteriorated, so it was restarted. She
also receives an intensive educational support program
with elements of Montessori homeschooling. Math exercises
are visualized, and her mother promotes social skills by
planning social activities regularly including outside events
(theater, horseback riding) and inviting schoolmates to the
home with prepared activities, encouraging phone calls with
familiar people, and running errands to the supermarket
independently built self-confident in socializing.
At 7 years 11 months of age, with cognitive testing uti-
lizing the Stanford-Binet, her full-scale IQ was 98, nonverbal
was 87, verbal was 105, fluid reasoning is 94, knowledge is
100, quantitative reasoning is 92, visual spatial abilities 100,
and working memory is 97. On the ADOS her score was
4 and in the normal range. On the Vineland, her commu-
nication score was 100, daily living skills was 83, socialization
was 83, and overall adaptive behavior composite was 87.
3. Discussion
We describe here two young children with FXS who have
a normal IQ. They have received intensive educational
intervention since early childhood by the mother, a teacher.
In addition they have had oﬀ-label psychopharmacological
interventions. Prior to the combined treatment, both of the
children have a developmental history suggesting significant
problems related to the full mutation. Case 2 has a low AR
of 0.2, and this would be associated with a lower IQ within
the broad range of involvement in females [19]. Only 13%
of boys with a full mutation have an IQ >70 [16], and an IQ
of 94 is very rare [4]; moreover he has 90%methylated alleles
which suggests that his IQ would not be high. However, these
children demonstrated remarkable behavioral changes and
learning ability on the combined medical and educational
interventions they received. It is likely that their intensive
intervention had a positive eﬀect on their cognitive ability.
Memantine, an N-methyl-D-aspartic acid (NMDA) non-
competitive receptor antagonist, is a neuroprotective agent
that blocks glutamate toxicity and restores homeostasis in
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the glutamatergic system [20], and this system is upregu-
lated in FXS. The NMDA receptor has been involved in
the pathophysiology of autism, and studies have reported
improvement of disruptive and aggressive behavior in autism
spectrum disorders (ASDs) with memantine [21–23]. Cur-
rently, memantine is undergoing controlled trials in autism
[21], and open-label in FXS with comorbid ASD had been
done showing eﬃcacy [24].
Sertraline is a selective serotonin reuptake inhibitor
(SSRI) used with demonstrated eﬃcacy in depression, anx-
iety, and obsessive compulsive disorders (OCDs) [25]. Low
doses of sertraline have minimal adverse eﬀects compared
to other SSRIs with less activation and reported benefit
in children [5, 26]. SSRIs have been known to stimulate
neurogenesis [27, 28]. A recent report of the use of another
SSRI, fluoxetine, in the mouse model of Down syndrome
demonstrated enhanced neurogenesis when used after birth
with increased levels of brain-derived neurotropic factor
(BDNF) and enhancement in cognition [29]. BDNF will
rescue the synaptic deficits of FXS [30]. Previous studies
suggested improvements in behavior and language with the
use of SSRIs in younger children with FXS or autism [31, 32].
Approximately 70% of individuals with FXS respond well to
fluoxetine with improvements in anxiety and aggression in
one open-label study, but hyperarousal was seen in 25% [33].
The third medication utilized is minocycline which
lowers MMP9 levels which are too high in FXS. Minocycline
leads to dendritic spine maturation both in culture and in
vivo FMR1 knock-out (KO) mice and improves behavior
and cognition [7]. The beneficial eﬀect of minocycline
has been reported in approximately 70% in a survey of
50 patients with FXS especially in language and behavior
[12]. An open-label study of 20 individuals with FXS who
were 13–32 years old treated for 8 weeks with minocycline
demonstrated improvements with minor side eﬀect [11].
A recent study demonstrated that minocycline significantly
potentiated nerve-growth-factor- (NGF-) induced neurite
outgrowth in PC12 cells [34]. Moreover, a marked increase of
the eukaryotic translation initiation factor (eIF4A1) protein
is induced by minocycline, which may be involved in the
active mechanism for NGF-induced neurite outgrowth [34].
Excellent enrichment of the environment by parents is
another important aspect of their treatment. Spike-timing-
dependent long-term potentiation (tLTP) in the prefrontal
cortex, which is involved in higher cognitive function,
was restored to wild-type (WT) level by an environmental
enrichment in the Fmr1 KO mouse [35]. In another study
of the fmr1 KO mouse an enriched environment rescued the
abnormalities of the dendritic spines [36].
Overall the combination of intensive education and the
incremental eﬀect of three oﬀ-label medications had remark-
able eﬀect on behavior and cognition in these children
[5]. Although background genetic eﬀects may have had
an important influence, their initial significant phenotypic
involvement with FXS followed by improvements with com-
bined therapy is noteworthy in these cases. These histories
suggest that aggressive early treatment in FXS can lead to an
excellent outcome.
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